Neovasculgen®

DRUG4 trials

Sponsors

Artgen Biotech, JSC NextGen

Conditions

Bladder Pain SyndromeHunner Type Interstitial CystitisICInterstitial Cystitis and Bladder Pain SyndromeInterstitial Cystitis, ChronicLower Limb IschemiaMellitus DiabetesUlcer Foot

Phase 2

The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's Lesions.

RecruitingNCT07391306

JSC NextGenIC, Interstitial Cystitis and Bladder Pain Syndrome, Interstitial Cystitis, Chronic

Start: 2024-02-16End: 2027-05-31Target: 180Updated: 2026-02-05

The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions

RecruitingNCT07459790

JSC NextGenBladder Pain Syndrome, Hunner Type Interstitial Cystitis, IC

Start: 2023-12-29End: 2027-10-30Target: 180Updated: 2026-03-10

Phase 3

The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial

RecruitingNCT07391319

JSC NextGenMellitus Diabetes, Ulcer Foot

Start: 2025-02-11End: 2027-03-31Target: 144Updated: 2026-02-05

Phase 4

Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia

CompletedNCT02369809

Artgen BiotechLower Limb Ischemia

Start: 2012-09-30End: 2017-01-31Updated: 2017-02-28

Related Papers

Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease.

2017-06-0133 citations